$836 Million is the total value of Cormorant Asset Management, LP's 82 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 128.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $35,468,000 | +59.7% | 400,000 | +33.3% | 4.24% | +19.6% |
| QTNT | Buy | QUOTIENT LTD | $24,306,000 | +67.1% | 1,519,100 | +35.7% | 2.91% | +25.1% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $23,064,000 | +105.0% | 245,000 | +75.0% | 2.76% | +53.5% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $18,365,000 | +80.8% | 315,000 | +31.2% | 2.20% | +35.5% |
| ACRS | New | ACLARIS THERAPEUTICS INC | $17,456,000 | – | 647,944 | +100.0% | 2.09% | – |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $15,653,000 | +78.3% | 495,356 | +94.3% | 1.87% | +33.6% |
| MGNX | New | MACROGENICS INC | $15,485,000 | – | 500,000 | +100.0% | 1.85% | – |
| CLLS | Buy | CELLECTIS SAsponsored ads | $14,558,000 | +4785.2% | 469,145 | +4051.7% | 1.74% | +3529.2% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $12,893,000 | +195.9% | 765,156 | +92.5% | 1.54% | +121.6% |
| VTAE | New | VITAE PHARMACEUTICALS INC | $11,284,000 | – | 623,409 | +100.0% | 1.35% | – |
| MYOK | New | MYOKARDIA INC | $11,045,000 | – | 753,388 | +100.0% | 1.32% | – |
| CTMX | New | CYTOMX THERAPEUTICS INC | $7,743,000 | – | 371,023 | +100.0% | 0.93% | – |
| WVE | New | WAVE LIFE SCIENCES PTE LTD | $6,254,000 | – | 392,079 | +100.0% | 0.75% | – |
| BLCM | New | BELLICUM PHARMACEUTICALS INC | $6,081,000 | – | 300,000 | +100.0% | 0.73% | – |
| ACHN | New | ACHILLION PHARMACEUTICALS IN | $5,395,000 | – | 500,000 | +100.0% | 0.64% | – |
| THLD | New | THRESHOLD PHARMACEUTICALS INC | $480,000 | – | 1,000,000 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.